spironolactone has been researched along with Cardiomyopathies in 41 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study suggests that spironolactone is well tolerated, and preliminary results support further investigation to evaluate the efficacy of spironolactone in the treatment of cats with cardiac failure due to cardiomyopathy." | 9.27 | The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy. ( Cobb, M; Garelli-Paar, C; Grassi, V; Guillot, E; Huxley, J; James, R, 2018) |
| " We investigated whether the effect of spironolactone on LVDD in patients with heart failure with preserved ejection fraction (HFpEF) depends on its effects on collagen cross-linking and/or deposition." | 9.27 | Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. ( Bach, D; Bachran, D; Delles, C; Díez, J; Dominiczak, AF; Edelmann, F; González, A; Hasenfuss, G; López, B; Pieske, B; Ravassa, S; Trippel, T; Wachter, R, 2018) |
| "The HOMAGE (Heart 'OMics' in AGEing) trial showed that spironolactone decreased serum PICP concentrations and improved cardiac remodelling over 9 months in a population at risk of developing heart failure (HF)." | 8.12 | The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. ( Bozec, E; Clark, AL; Cleland, JGF; Cosmi, F; Cuthbert, J; Diez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Hazebroek, M; Heymans, S; Huttin, O; Kevin, D; Kobayashi, M; Mariottoni, B; Pellicori, P; Petutschnigg, J; Pieske, B; Rossignol, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2022) |
| " Administration of angiotensin II and Nomega-nitro-L-arginine methyl ester (L-NAME; nitric oxide synthesis inhibitor) to male rats drinking 1% saline caused hypertension, severe biventricular myocardial necrosis, proteinuria, and fibrinoid necrosis of renal and cardiac vessels." | 7.70 | Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. ( Adler, GK; Kifor, I; Ochoa-Maya, MR; Rennke, HG; Rocha, R; Stier, CT; Williams, GH, 2000) |
| "This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure." | 6.41 | Aldosterone and myocardial fibrosis in heart failure. ( Brilla, CG, 2000) |
| "Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure." | 5.29 | Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995) |
| "Spironolactone, however, was able to prevent myocardial fibrosis in RHT and aldosterone models of acquired arterial hypertension irrespective of the development of LVH and the presence of hypertension." | 5.29 | Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. ( Brilla, CG; Matsubara, LS; Weber, KT, 1993) |
| "This study suggests that spironolactone is well tolerated, and preliminary results support further investigation to evaluate the efficacy of spironolactone in the treatment of cats with cardiac failure due to cardiomyopathy." | 5.27 | The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy. ( Cobb, M; Garelli-Paar, C; Grassi, V; Guillot, E; Huxley, J; James, R, 2018) |
| " We investigated whether the effect of spironolactone on LVDD in patients with heart failure with preserved ejection fraction (HFpEF) depends on its effects on collagen cross-linking and/or deposition." | 5.27 | Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. ( Bach, D; Bachran, D; Delles, C; Díez, J; Dominiczak, AF; Edelmann, F; González, A; Hasenfuss, G; López, B; Pieske, B; Ravassa, S; Trippel, T; Wachter, R, 2018) |
| "The HOMAGE (Heart 'OMics' in AGEing) trial showed that spironolactone decreased serum PICP concentrations and improved cardiac remodelling over 9 months in a population at risk of developing heart failure (HF)." | 4.12 | The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. ( Bozec, E; Clark, AL; Cleland, JGF; Cosmi, F; Cuthbert, J; Diez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Hazebroek, M; Heymans, S; Huttin, O; Kevin, D; Kobayashi, M; Mariottoni, B; Pellicori, P; Petutschnigg, J; Pieske, B; Rossignol, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2022) |
| " Administration of angiotensin II and Nomega-nitro-L-arginine methyl ester (L-NAME; nitric oxide synthesis inhibitor) to male rats drinking 1% saline caused hypertension, severe biventricular myocardial necrosis, proteinuria, and fibrinoid necrosis of renal and cardiac vessels." | 3.70 | Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. ( Adler, GK; Kifor, I; Ochoa-Maya, MR; Rennke, HG; Rocha, R; Stier, CT; Williams, GH, 2000) |
| "In boys with Duchenne muscular dystrophy and preserved ejection fraction, addition of eplerenone to background ACEI or ARB therapy attenuates the progressive decline in left ventricular systolic function." | 2.80 | Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. ( Cripe, LH; Halnon, NJ; He, X; Hor, KN; Jefferies, JL; Kissel, JT; Lowe, J; Mazur, W; McCarthy, B; Rafael-Fortney, JA; Raman, SV; Roble, SL; Smart, S; Taylor, MD; Tran, T, 2015) |
| "This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure." | 2.41 | Aldosterone and myocardial fibrosis in heart failure. ( Brilla, CG, 2000) |
| "In conclusion, hypokalemia is extremely common in patients presenting with VT/VF, much more so than in patients with CHF alone." | 1.56 | Electrolyte Abnormalities in Patients Presenting With Ventricular Arrhythmia (from the LYTE-VT Study). ( Basil, A; Cooper, JM; Gangireddy, C; Greenberg, RM; Laslett, DB; Whitman, IR; Yesenosky, GA, 2020) |
| "As life expectancy of patients with Duchenne muscular dystrophy (DMD) has increased to the 5th decade, in part due to improved ventilatory support, cardiomyopathy is projected to increase as a cause of death." | 1.40 | Cardiac management of ventilator-assisted individuals with Duchenne muscular dystrophy. ( Evans, RA; Goldstein, RS; O'Brien, L; Varadi, R, 2014) |
| "We retrospectively evaluated the ventricular tachycardia (VT) rates in patients with structural heart disease actively treated with therapies with antifibrotic properties." | 1.37 | Spironolactone therapy is associated with reduced ventricular tachycardia rate in patients with cardiomyopathy. ( Ayers, C; Daniels, J; Dimas, V; Hill, JA; Joglar, JA; Naseem, RH, 2011) |
| "Nearly universal cardiomyopathy in Duchenne muscular dystrophy (DMD) contributes to heart failure and death." | 1.37 | Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. ( Canan, BD; Chimanji, NS; Delfín, DA; Ganguly, R; Janssen, PM; Martin, CD; Mays, TA; Murray, JD; Rafael-Fortney, JA; Raman, SV; Schill, KE; Stangland, JE; Tran, T; Xu, Y, 2011) |
| "The influence of chronic administration of eplerenone on the intracrine as well as on the extracellular action of angiotensin II (Ang II) on L-type inward calcium current was investigated in the failing heart of cardiomyopathic hamsters (TO-2)." | 1.35 | Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system. ( De Mello, WC; Gerena, Y, 2008) |
| "Spironolactone has been noted to attenuate cardiac fibrosis." | 1.35 | Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. ( Bagrov, AY; Cooper, CJ; El-Okdi, N; Elkareh, J; Fedorova, OV; Gohara, S; Gupta, S; Haller, S; Malhotra, D; Periyasamy, SM; Shapiro, JI; Shidyak, A; Taleb, M; Tian, J; Xie, Z, 2009) |
| "Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure." | 1.29 | Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995) |
| "Spironolactone, however, was able to prevent myocardial fibrosis in RHT and aldosterone models of acquired arterial hypertension irrespective of the development of LVH and the presence of hypertension." | 1.29 | Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. ( Brilla, CG; Matsubara, LS; Weber, KT, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (17.07) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 8 (19.51) | 29.6817 |
| 2010's | 17 (41.46) | 24.3611 |
| 2020's | 7 (17.07) | 2.80 |
| Authors | Studies |
|---|---|
| Yokota, T | 1 |
| Koiwa, H | 1 |
| Matsushima, S | 1 |
| Tsujinaga, S | 1 |
| Naya, M | 1 |
| Morisaki, H | 1 |
| Morisaki, T | 1 |
| Kobayashi, M | 1 |
| Girerd, N | 1 |
| Ferreira, JP | 1 |
| Kevin, D | 1 |
| Huttin, O | 1 |
| González, A | 2 |
| Bozec, E | 1 |
| Clark, AL | 1 |
| Cosmi, F | 1 |
| Cuthbert, J | 1 |
| Diez, J | 2 |
| Edelmann, F | 2 |
| Hazebroek, M | 1 |
| Heymans, S | 1 |
| Mariottoni, B | 1 |
| Pellicori, P | 1 |
| Petutschnigg, J | 1 |
| Pieske, B | 2 |
| Staessen, JA | 1 |
| Verdonschot, JAJ | 1 |
| Rossignol, P | 1 |
| Cleland, JGF | 1 |
| Zannad, F | 1 |
| Mandal, C | 1 |
| Dutta, PK | 1 |
| Kim, MM | 1 |
| Prasad, M | 1 |
| Burton, Y | 1 |
| Kolseth, CM | 1 |
| Zhao, Y | 1 |
| Chandrashekar, P | 1 |
| Nazer, B | 1 |
| Masri, A | 1 |
| Raman, SV | 4 |
| Hor, KN | 3 |
| Mazur, W | 3 |
| Cardona, A | 1 |
| He, X | 3 |
| Halnon, N | 1 |
| Markham, L | 1 |
| Soslow, JH | 1 |
| Puchalski, MD | 1 |
| Auerbach, SR | 1 |
| Truong, U | 1 |
| Smart, S | 3 |
| McCarthy, B | 3 |
| Saeed, IM | 1 |
| Statland, JM | 1 |
| Kissel, JT | 3 |
| Cripe, LH | 3 |
| Laslett, DB | 1 |
| Cooper, JM | 1 |
| Greenberg, RM | 1 |
| Yesenosky, GA | 1 |
| Basil, A | 1 |
| Gangireddy, C | 1 |
| Whitman, IR | 1 |
| Birnkrant, DJ | 1 |
| Black, JB | 1 |
| Huang, Y | 1 |
| Liu, H | 1 |
| Wu, C | 1 |
| Fang, L | 1 |
| Fang, Q | 1 |
| Wang, Q | 1 |
| Fei, Y | 1 |
| Guo, X | 1 |
| Zhang, S | 1 |
| James, R | 1 |
| Guillot, E | 1 |
| Garelli-Paar, C | 1 |
| Huxley, J | 1 |
| Grassi, V | 1 |
| Cobb, M | 1 |
| Ravassa, S | 1 |
| Trippel, T | 1 |
| Bach, D | 1 |
| Bachran, D | 1 |
| López, B | 1 |
| Wachter, R | 1 |
| Hasenfuss, G | 1 |
| Delles, C | 1 |
| Dominiczak, AF | 1 |
| Huang, M | 1 |
| Liu, J | 1 |
| Sheng, Y | 1 |
| Lv, Y | 1 |
| Yu, J | 1 |
| Qi, H | 1 |
| Di, W | 1 |
| Lv, S | 1 |
| Zhou, S | 1 |
| Ding, G | 1 |
| O'Brien, L | 1 |
| Varadi, R | 1 |
| Goldstein, RS | 1 |
| Evans, RA | 1 |
| Lewey, J | 1 |
| Haythe, J | 1 |
| Celtik, C | 1 |
| Durmaz, O | 1 |
| Oner, N | 1 |
| Yavuz, T | 1 |
| Gökce, S | 1 |
| Aydogan, A | 1 |
| Nisli, K | 1 |
| Emiroglu, HH | 1 |
| Ömeroglu, RE | 1 |
| Sökücü, S | 1 |
| Akpek, M | 1 |
| Ozdogru, I | 1 |
| Sahin, O | 1 |
| Inanc, M | 1 |
| Dogan, A | 1 |
| Yazici, C | 1 |
| Berk, V | 1 |
| Karaca, H | 1 |
| Kalay, N | 1 |
| Oguzhan, A | 1 |
| Ergin, A | 1 |
| Angelini, C | 1 |
| Halnon, NJ | 1 |
| Tran, T | 2 |
| Taylor, MD | 1 |
| Jefferies, JL | 1 |
| Rafael-Fortney, JA | 2 |
| Lowe, J | 1 |
| Roble, SL | 2 |
| Condorelli, G | 1 |
| Jotti, GS | 1 |
| Pagiatakis, C | 1 |
| De Mello, WC | 1 |
| Gerena, Y | 1 |
| Rasmussen, ZZ | 1 |
| Barfod, T | 1 |
| Klit, J | 1 |
| Cosín-Aguilar, J | 1 |
| Hernándiz-Martínez, A | 1 |
| Aguilar-Llopis, A | 1 |
| Portolés-Sanz, M | 1 |
| Díez-Gil, JL | 1 |
| Tian, J | 1 |
| Shidyak, A | 1 |
| Periyasamy, SM | 1 |
| Haller, S | 1 |
| Taleb, M | 1 |
| El-Okdi, N | 1 |
| Elkareh, J | 1 |
| Gupta, S | 1 |
| Gohara, S | 1 |
| Fedorova, OV | 1 |
| Cooper, CJ | 1 |
| Xie, Z | 1 |
| Malhotra, D | 1 |
| Bagrov, AY | 1 |
| Shapiro, JI | 1 |
| Susic, D | 1 |
| Varagic, J | 1 |
| Frohlich, ED | 1 |
| Dimas, V | 1 |
| Ayers, C | 1 |
| Daniels, J | 1 |
| Joglar, JA | 1 |
| Hill, JA | 1 |
| Naseem, RH | 1 |
| Strobel, J | 1 |
| Schröder, S | 1 |
| Chimanji, NS | 1 |
| Schill, KE | 1 |
| Martin, CD | 1 |
| Murray, JD | 1 |
| Ganguly, R | 1 |
| Stangland, JE | 1 |
| Xu, Y | 1 |
| Canan, BD | 1 |
| Mays, TA | 1 |
| Delfín, DA | 1 |
| Janssen, PM | 1 |
| Lee, T | 1 |
| Sun, Y | 1 |
| Zhang, J | 1 |
| Lu, L | 1 |
| Chen, SS | 1 |
| Quinn, MT | 1 |
| Weber, KT | 2 |
| Rickard, AJ | 1 |
| Funder, JW | 1 |
| Morgan, J | 1 |
| Fuller, PJ | 1 |
| Young, MJ | 1 |
| Widman, L | 1 |
| Dyckner, T | 1 |
| Wester, PO | 1 |
| Nicoletti, A | 1 |
| Heudes, D | 1 |
| Hinglais, N | 1 |
| Appay, MD | 1 |
| Philippe, M | 1 |
| Sassy-Prigent, C | 1 |
| Bariety, J | 1 |
| Michel, JB | 1 |
| Brilla, CG | 2 |
| Matsubara, LS | 1 |
| Rocha, R | 1 |
| Stier, CT | 1 |
| Kifor, I | 1 |
| Ochoa-Maya, MR | 1 |
| Rennke, HG | 1 |
| Williams, GH | 1 |
| Adler, GK | 1 |
| Perchikova, GE | 1 |
| Tsibekmakher, TD | 1 |
| Selye, H | 1 |
| Gardell, C | 1 |
| Blascheck, JA | 1 |
| Kovacs, K | 1 |
| Savoie, L | 1 |
| Krajny, M | 1 |
| Kleiman, B | 1 |
| Yasui, H | 1 |
| Moudgil, LR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy[NCT02354352] | Phase 3 | 52 participants (Actual) | Interventional | 2015-03-20 | Completed | ||
| The Transition From Hypertension to Hypertensive Heart Disease and Heart Failure, the PREFERS Hypertension Study[NCT04190420] | 310 participants (Anticipated) | Observational | 2018-10-01 | Enrolling by invitation | |||
| Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)[NCT06005259] | Phase 4 | 264 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| Protective Effects of Spironolactone Against Anthracycline Induced Cardiomyopathy[NCT02053974] | Phase 4 | 90 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)[NCT03439670] | Phase 2 | 121 participants (Actual) | Interventional | 2018-06-29 | Completed | ||
| Early Treatment With Aldosterone Antagonism Attenuates Cardiomyopathy in Duchenne Muscular Dystrophy[NCT01521546] | 42 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658] | Phase 3 | 90 participants (Anticipated) | Interventional | 2017-08-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
a sensitive measure of heart muscle function (NCT02354352)
Timeframe: 12 months
| Intervention | Percent change in circumference (Median) |
|---|---|
| Eplerenone | 0.2 |
| Spironolactone | 0.4 |
Vamorolone at 6.0mg/kg/day vs. placebo group in change from baseline to the Week 24 assessment (NCT03439670)
Timeframe: 24 weeks
| Intervention | Rises/Seconds (Mean) |
|---|---|
| Treatment Group 1 | -.007 |
| Treatment Group 2 | 0.054 |
a sensitive measurement of heart function using cardiac MRI, change was 12 months minus baseline. (NCT01521546)
Timeframe: baseline and 12 months
| Intervention | percent change in heart dimension (Median) |
|---|---|
| Placebo | 2.2 |
| Eplerenone | 1.0 |
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
3 reviews available for spironolactone and Cardiomyopathies
| Article | Year |
|---|---|
Year in review 2019: Neuromuscular diseases.
Topics: Cardiomyopathies; Humans; Morpholinos; Muscular Dystrophy, Duchenne; Oxadiazoles; Spironolactone | 2020 |
Cardiomyopathy in pregnancy.
Topics: Adrenergic beta-Antagonists; Adult; Anesthesia, Obstetrical; Angiotensin-Converting Enzyme Inhibitor | 2014 |
Aldosterone and myocardial fibrosis in heart failure.
Topics: Adult; Aldosterone; Animals; Cardiomyopathies; Dose-Response Relationship, Drug; Fibrosis; Heart Fai | 2000 |
7 trials available for spironolactone and Cardiomyopathies
| Article | Year |
|---|---|
Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial.
Topics: Adolescent; Cardiomyopathies; Child; Double-Blind Method; Eplerenone; Humans; Magnetic Resonance Ima | 2019 |
The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathies; Cat Diseases; Cats; Diuretics; | 2018 |
Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Topics: Aged; Biomarkers; Cardiomyopathies; Disease Progression; Dose-Response Relationship, Drug; Double-Bl | 2018 |
Protective effects of spironolactone against anthracycline-induced cardiomyopathy.
Topics: Adult; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiomyopathies; Double-Blind | 2015 |
Protective effects of spironolactone against anthracycline-induced cardiomyopathy.
Topics: Adult; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiomyopathies; Double-Blind | 2015 |
Protective effects of spironolactone against anthracycline-induced cardiomyopathy.
Topics: Adult; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiomyopathies; Double-Blind | 2015 |
Protective effects of spironolactone against anthracycline-induced cardiomyopathy.
Topics: Adult; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiomyopathies; Double-Blind | 2015 |
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Cardiomyopathies; Child; Cohort Studies; Double-Blind Method; Early Diagnosis; Eplerenon | 2015 |
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Cardiomyopathies; Child; Cohort Studies; Double-Blind Method; Early Diagnosis; Eplerenon | 2015 |
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Cardiomyopathies; Child; Cohort Studies; Double-Blind Method; Early Diagnosis; Eplerenon | 2015 |
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Cardiomyopathies; Child; Cohort Studies; Double-Blind Method; Early Diagnosis; Eplerenon | 2015 |
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial.
Topics: Adolescent; Adult; Cardiomyopathies; Child; Double-Blind Method; Eplerenone; Humans; Male; Mineraloc | 2017 |
Effect of moduretic and aldactone on electrolytes in skeletal muscle in patients on long-term diuretic therapy.
Topics: Cardiomyopathies; Humans; Hydrochlorothiazide; Hypertension; Magnesium; Muscles; Potassium; Spironol | 1982 |
31 other studies available for spironolactone and Cardiomyopathies
| Article | Year |
|---|---|
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure.
Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; | 2022 |
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
Topics: Biomarkers; Cardiomyopathies; Clinical Trials as Topic; Collagen Type I; Collagen Type III; Echocard | 2022 |
Unique Case of Cardiomyopathy Secondary to Adrenal Adenoma (Primary-Aldosteronism).
Topics: Adenoma; Adrenocortical Adenoma; Aldosterone; Cardiomyopathies; Female; Humans; Hyperaldosteronism; | 2023 |
Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial.
Topics: Amyloidosis; Cardiomyopathies; Heart Failure; Humans; Prealbumin; Spironolactone; Stroke Volume; Tre | 2023 |
Electrolyte Abnormalities in Patients Presenting With Ventricular Arrhythmia (from the LYTE-VT Study).
Topics: Aged; Cardiomyopathies; Case-Control Studies; Diarrhea; Diuretics; Female; Heart Failure; Humans; Hy | 2020 |
Ventricular arrhythmia predicts poor outcome in polymyositis/dermatomyositis with myocardial involvement.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 2021 |
11β-hydroxysteroid dehydrogenase type 1 inhibitor attenuates high-fat diet induced cardiomyopathy.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Animals, Newborn; Calcium Signaling; Cardiomyo | 2018 |
Cardiac management of ventilator-assisted individuals with Duchenne muscular dystrophy.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Diur | 2014 |
Investigation of cardiomyopathy in children with cirrhotic and noncirrhotic portal hypertension.
Topics: Adolescent; Antihypertensive Agents; Ascites; Blood Pressure; Cardiomyopathies; Case-Control Studies | 2015 |
Prevention of cardiomyopathy in Duchenne muscular dystrophy.
Topics: Cardiomyopathies; Eplerenone; Humans; Male; Mineralocorticoid Receptor Antagonists; Muscular Dystrop | 2015 |
Fibroblast Senescence as a Therapeutic Target of Myocardial Fibrosis: Beyond Spironolactone?
Topics: Cardiomyopathies; Fibroblasts; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonis | 2016 |
Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Ca | 2008 |
[Renal effect of treatment for heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Diuretics; Furosemide; Heart Failure; Hu | 2009 |
Prevention of myocardial dysfunction by Eplerenon in experimental tachycardiomyopathy.
Topics: Animals; Cardiomyopathies; Eplerenone; Female; Male; Mineralocorticoid Receptor Antagonists; Spirono | 2009 |
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.
Topics: Animals; Bufanolides; Canrenone; Cardiomyopathies; Cardiotonic Agents; Cells, Cultured; Disease Mode | 2009 |
Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2010 |
Spironolactone therapy is associated with reduced ventricular tachycardia rate in patients with cardiomyopathy.
Topics: Aged; Cardiomyopathies; Comorbidity; Diuretics; Female; Heart Rate; Humans; Male; Middle Aged; Preva | 2011 |
[Postpartum cardiomyopathy].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Anticoagula | 2011 |
Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice.
Topics: Animals; Cardiac Imaging Techniques; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; D | 2011 |
Ask the doctor. My 69-year-old husband has had cardiomyopathy and diabetes for several years. Lately his ankles are always swollen. At his last doctor's visit, my husband's cardiologist said his heart has leaky valves and his ejection fraction is 10%. Wha
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Diabe | 2011 |
Aldosterone-induced inflammation in the rat heart : role of oxidative stress.
Topics: Aldosterone; Animals; Antioxidants; Cardiomyopathies; Cell Division; Cell Movement; Fibrosis; Heart; | 2002 |
Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration?
Topics: Animals; Biomarkers; Blood Pressure; Cardiomegaly; Cardiomyopathies; Coronary Vessels; Desoxycortico | 2007 |
Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biochemical Phen | 1995 |
Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomyopathies; Fibrosis; Hyperaldosteronism; Hypertension; | 1993 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
[Treatment of refractory chronic circulatory insufficiency].
Topics: Adult; Aged; Benzothiadiazines; Cardiac Glycosides; Cardiomyopathies; Chronic Disease; Coronary Dise | 1976 |
Prevention of various forms of metabolic myocardial necrosis by catatoxic steroids.
Topics: Animals; Cardiomyopathies; Desoxycorticosterone; Digitoxin; Disease Models, Animal; Ethylestrenol; F | 1970 |
[Spironolactone protection against experimental cardiopathy due to digitoxin, disodium phosphate and oil].
Topics: Animals; Cardiomyopathies; Digitoxin; Enzyme Induction; Heart; Microscopy, Electron; Myocardium; Nec | 1970 |
Digitoxin induced cardiac necrosis and its inhibition.
Topics: Animals; Cardiomyopathies; Digitoxin; Drug Synergism; Enzyme Induction; Female; Heart; Injections, S | 1969 |
The role of catecholamines in circulatory regulation on the chronic congestive heart failure. Clinical study of the urinary catecholamine excretion in the patients with chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cardiomyopathies; Catecholamines; Coronary Disease; Digital | 1968 |
Possible protective action of antialdosterone compounds in myocardial necrosis in rats.
Topics: Animals; Cardiomyopathies; Isoproterenol; Mineralocorticoid Receptor Antagonists; Necrosis; Rats; Sp | 1969 |